Glucocerebrosidase Activity Is Not Associated with Parkinson's Disease Risk or Severity

Nurit Omer^{1

2

3}, Nir Giladi^{1

2

4}, Tanya Gurevich^{1

2

4}, Anat Bar-Shira⁵, Mali Gana-Weisz⁶, Tal Glinka⁶, Orly Goldstein⁶, Meir Kestenbaum⁷, Jesse M Cedarbaum^{8

9}, Omar S Mabrouk⁸, Kyle B Fraser⁸, Julia C Shirvan⁸, Avi Orr-Urtreger^{2

6}, Anat Mirelman^{2

3

4}, Avner Thaler^{1

2

3

4}

Affiliations

¹ Movement Disorders Unit, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.
² Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
³ Laboratory of Early Markers of Neurodegeneration, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.
⁴ Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel.
⁵ Genetic Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.
⁶ Genomic Research Laboratory for Neurodegeneration, Tel-Aviv Medical Center, Tel-Aviv, Israel.
⁷ Neurology Department, Meir Medical Center, Kfar-Saba, Israel.
⁸ Biogen Inc, Cambridge, Massachusetts, USA.
⁹ Coeruleus Clinical Sciences LLC, Woodbridge, Connecticut, USA.

Comment

Nurit Omer et al. Mov Disord. 2022 Mar.

. 2022 Mar;37(3):651-652.

doi: 10.1002/mds.28929. Epub 2022 Jan 22.

¹ Movement Disorders Unit, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.
² Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
³ Laboratory of Early Markers of Neurodegeneration, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.
⁴ Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel.
⁵ Genetic Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.
⁶ Genomic Research Laboratory for Neurodegeneration, Tel-Aviv Medical Center, Tel-Aviv, Israel.
⁷ Neurology Department, Meir Medical Center, Kfar-Saba, Israel.
⁸ Biogen Inc, Cambridge, Massachusetts, USA.
⁹ Coeruleus Clinical Sciences LLC, Woodbridge, Connecticut, USA.

No abstract available

Comment on

Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity.
Omer N, Giladi N, Gurevich T, Bar-Shira A, Gana-Weisz M, Glinka T, Goldstein O, Kestenbaum M, Cedarbaum JM, Mabrouk OS, Fraser KB, Shirvan JC, Orr-Urtreger A, Mirelman A, Thaler A. Omer N, et al. Mov Disord. 2022 Jan;37(1):190-195. doi: 10.1002/mds.28792. Epub 2021 Sep 22. Mov Disord. 2022. PMID: 34550621 Free PMC article.
The Jury Is Still Out.
Lansbury P. Lansbury P. Mov Disord. 2022 Mar;37(3):651. doi: 10.1002/mds.28911. Epub 2022 Jan 17. Mov Disord. 2022. PMID: 35040206 No abstract available.

1. Alcalay RN, Wolf P, Chiang MSR, et al. Longitudinal measurements of glucocerebrosidase activity in Parkinson's patients. Ann Clin Transl Neurol 2020;7(10):1816-1830. https://doi.org/10.1002/acn3.51164 [published Online First: Epub Date]
1. Alcalay RN, Levy OA, Waters CC, et al. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain 2015;138(Pt 9):2648-2658. https://doi.org/10.1093/brain/awv179 [published Online First: Epub Date]
1. Omer N, Giladi N, Gurevich T, et al. Glucocerebrosidase activity is not associated with Parkinson's disease risk or severity. Mov Disord 2021. https://doi.org/10.1002/mds.28792 [published Online First: Epub Date]
1. Heinzel S, Berg D, Gasser T, et al. Update of the MDS research criteria for prodromal Parkinson's disease. Mov Disord 2019;34(10):1464-1470. https://doi.org/10.1002/mds.27802 [published Online First: Epub Date]
1. Kozlovski T, Mitelpunkt A, Thaler A, et al. Hierarchical data-driven analysis of clinical symptoms among patients with Parkinson's disease. Front Neurol 2019;10:531. https://doi.org/10.3389/fneur.2019.00531 [published Online First: Epub Date]